(E/Z)-Zotiraciclib hydrochloride

• CAT Number: I043965
• CAS Number: 1321626-25-8
• Molecular Formula: C23H25ClN4O
• Molecular Weight: 408.92
• Purity: ≥95%
• Synonyms: (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene;hydrochloride
• InChI: InChI=1S/C23H24N4O.ClH/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27;/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26);1H/b3-2+
• InChIKey: YPVRSANPCYTWDF-SQQVDAMQSA-N
• SMILES: CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1.Cl

(E/Z)-Zotiraciclib hydrochloride（Cat No.:I043965）is a hydrochloride salt form of zotiraciclib, a potent cyclin-dependent kinase (CDK) inhibitor targeting CDK9 and related kinases critical for transcription and cancer cell survival. Comprising a mixture of E and Z isomers, it disrupts transcriptional regulation by inhibiting CDK9-mediated phosphorylation of RNA polymerase II, leading to downregulation of anti-apoptotic proteins such as Mcl-1. The hydrochloride formulation enhances solubility and bioavailability for clinical use. (E/Z)-Zotiraciclib hydrochloride is under investigation for treating glioblastoma and other cancers, demonstrating promising activity in preclinical and early-phase clinical studies.